A Study Of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration

Overview

About this study

The purpose of this study is to evaluate the median duration of therapeutic SAA levels with calaspargase pegol. Secondary end points include evaluating a potential association between peak SAA levels and duration of therapeutic levels with toxicity.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team.

  • Receiving calaspargase as part of treatment for malignancy.

 

Exclusion Criteria: 

  • Age >21 years.

  • Patients who are actively enrolled on COG trial AALL1732 in an inotuzumab containing arm.

  • Pregnancy

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 8/19/2025. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Madeleine O'Keefe, M.D.

Contact us for the latest status

Contact information:

Rebecca Winslow Rain

5072842657

winslowrain.rebecca@mayo.edu

More information

Publications

Publications are currently not available